Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityActive in the last 2 years

Tianlin He

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4146-3872; OpenAlex author ID A5109460864. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 8

  1. Enhancing preoperative diagnosis of pancreatic ductal adenocarcinoma and mass-forming chronic pancreatitis: a study on normalized conventional MR imaging param… Co-author DOI 10.1007/s00261-024-04652-7↗
  2. Retraction Note: The c-Myc-LDHA axis positively regulates aerobic glycolysis and promotes tumor progression in pancreatic cancer. Co-author DOI 10.1007/s12032-026-03296-5↗
  3. Menin regulates YBX1 nucleus translocation to boost the HKDC1 transcription and affects pancreatic cancer glycolysis. Co-author DOI 10.1016/j.isci.2025.113245↗
  4. Systemic therapy and perioperative management improve the prognosis of pancreatic ductal adenocarcinoma: A retrospective cohort study of 2000 consecutive cases. Co-author DOI 10.1016/j.ijsu.2022.106786↗
  5. Radical antegrade modular pancreatosplenectomy versus standard distal pancreatosplenectomy for pancreatic cancer, a dual-institutional analysis. Co-author DOI 10.21037/cco-20-6↗
  6. Menin Coordinates C/EBPβ-Mediated TGF-β Signaling for Epithelial-Mesenchymal Transition and Growth Inhibition in Pancreatic Cancer. Co-author DOI 10.1016/j.omtn.2019.08.013↗
  7. The c-Myc-LDHA axis positively regulates aerobic glycolysis and promotes tumor progression in pancreatic cancer. Co-author DOI 10.1007/s12032-015-0633-8↗
  8. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer. First author DOI 10.3892/or.2014.3595↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kailian Zheng · 2 shared papers, 2022–2026 · strength 0.48
  2. Gang Jin · 3 shared papers, 2019–2025 · strength 0.43
  3. Kai-Lian Zheng · 2 shared papers, 2015–2026 · strength 0.42
  4. Xiaohan Shi · 2 shared papers, 2022–2025 · strength 0.37
  5. Yuxiao Li · 1 shared paper, 2026 · strength 0.36
  6. Chenming Ni · 2 shared papers, 2019–2025 · strength 0.34
  7. Peng Cheng · 2 shared papers, 2019–2025 · strength 0.34
  8. Shiwei Guo · 3 shared papers, 2019–2022 · strength 0.31
  9. Yebin Lu · 1 shared paper, 2025 · strength 0.25
  10. Xiangui Hu · 2 shared papers, 2020–2022 · strength 0.21
  11. Gang Li · 2 shared papers, 2020–2022 · strength 0.21
  12. Suizhi Gao · 1 shared paper, 2022 · strength 0.13
  13. Shuo Shen · 1 shared paper, 2022 · strength 0.13
  14. Bo Li · 1 shared paper, 2022 · strength 0.13
  15. Guoxiao Zhang · 1 shared paper, 2022 · strength 0.13
  16. Gang Jin · 1 shared paper, 2022 · strength 0.13
  17. Xiaoyi Yin · 1 shared paper, 2022 · strength 0.13
  18. Bin Zhao · 1 shared paper, 2015 · strength 0.11
  19. Yijie Zhang · 1 shared paper, 2019 · strength 0.10
  20. Ding Ding · 1 shared paper, 2020 · strength 0.08
  21. Michele Maiko Gage · 1 shared paper, 2020 · strength 0.08
  22. Jin Peng He · 1 shared paper, 2020 · strength 0.08
  23. Jonathan G. Sham · 1 shared paper, 2020 · strength 0.08
  24. Richard Andrew Burkhart · 1 shared paper, 2020 · strength 0.08
  25. Michael J. Wright · 1 shared paper, 2020 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.